Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Rating) major shareholder Group Gp Lp Column III purchased 49,463 shares of the business’s stock in a transaction dated Tuesday, January 17th. The stock was bought at an average price of $2.49 per share, with a total value of $123,162.87. Following the acquisition, the insider now directly owns 9,664,847 shares in the company, valued at $24,065,469.03. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Tenaya Therapeutics Price Performance
Tenaya Therapeutics stock opened at $2.86 on Friday. Tenaya Therapeutics, Inc. has a 12-month low of $1.64 and a 12-month high of $16.17. The stock has a market capitalization of $118.33 million, a P/E ratio of -1.02 and a beta of 1.61. The firm’s 50-day moving average is $2.28 and its two-hundred day moving average is $3.40.
Tenaya Therapeutics (NASDAQ:TNYA – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). As a group, analysts forecast that Tenaya Therapeutics, Inc. will post -2.72 EPS for the current year.
Institutional Investors Weigh In On Tenaya Therapeutics
Analyst Ratings Changes
A number of brokerages recently commented on TNYA. Canaccord Genuity Group began coverage on shares of Tenaya Therapeutics in a research note on Monday, November 7th. They issued a “buy” rating on the stock. Chardan Capital lowered their price objective on shares of Tenaya Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. Finally, Canaccord Genuity Group began coverage on shares of Tenaya Therapeutics in a research note on Tuesday, November 8th. They issued a “buy” rating and a $21.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics has an average rating of “Buy” and an average price target of $24.67.
Tenaya Therapeutics Company Profile
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).
- Get a free copy of the StockNews.com research report on Tenaya Therapeutics (TNYA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.